Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage

OBJECTIVES: This study sought to assess the adherence of newly diagnosed hepatocellular carcinoma patients to the Barcelona Clinic Liver Cancer system treatment guidelines and to examine the impact of adherence on the survival of patients in different stages of the disease. METHODS: This study included all patients referred for the treatment of hepatocellular carcinoma between 2010 and 2012. Patients (n=364) were classified according to the Barcelona Clinic Liver Cancer guidelines. Deviations from the recommended guidelines were discussed, and treatment was determined by a multidisciplinary team. The overall survival curves were estimated with the Kaplan-Meier method and were compared using the log-rank test. RESULTS: The overall rate of adherence to the guidelines was 52%. The rate of adherence of patients in each scoring group varied as follows: stage 0, 33%; stage A, 45%; stage B, 78%; stage C, 35%; and stage D, 67%. In stage 0/A, adherent patients had a significantly better overall survival than non-adherent patients (hazard ratio=0.19, 95% confidence interval (CI): 0.09-0.42; p<0.001). Among the stage D patients, the overall survival rate was worse in adherent patients than in non-adherent patients (hazard ratio=4.0, 95% CI: 1.67-9.88; p<0.001), whereas no differences were observed in patients in stages B or C. CONCLUSIONS: The rate of adherence to the Barcelona Clinic Liver Cancer staging system in clinical practice varies according to clinical disease stage. Adherence to the recommended guidelines positively impacts survival, especially in patients with early-stage disease.

Palavras-chave

Hepatocellular Carcinoma, Prognosis, Tumor Staging, Guideline Adherence

URI

https://observatorio.fm.usp.br/handle/OPI/24267

Referências

Bolondi L, 2012, SEMIN LIVER DIS, V32, P348, DOI 10.1055/s-0032-1329906
Borzio M, 2013, FUTURE ONCOL, V9, P283, DOI [10.2217/fon.12.183, 10.2217/FON.12.183]
Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933
Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1
Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
Burrel M, 2012, J HEPATOL, V56, P1330, DOI 10.1016/j.jhep.2012.01.008
D'Avola D, 2011, ANN SURG ONCOL, V18, P1964, DOI 10.1245/s10434-011-1551-4
El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
El-Serag HB, 2006, J HEPATOL, V44, P158, DOI 10.1016/j.jhep.2005.10.002
Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
Fomer A, 2014, NAT REV CLIN ONCOL, V11, P525, DOI 10.1038/nrclinonc.2014.122
Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
Guarino M, 2015, J MED VIROL, V87, P1368, DOI 10.1002/jmv.24187
Kim BK, 2012, LIVER INT, V32, P1120, DOI 10.1111/j.1478-3231.2012.02811.x
김성은, 2011, Clinical and Molecular Hepatology, V17, P113
Leoni S, 2014, DIGEST LIVER DIS, V46, P549, DOI 10.1016/j.dld.2014.02.012
Llovet JM, 2012, J HEPATOL, V56, P908
Piscaglia F, 2013, DIGEST LIVER DIS, V45, P852, DOI 10.1016/j.dld.2013.03.002
R Development Core Team, 2011, R LANG ENV STAT COMP
Radu P, 2013, J GASTROINTEST LIVER, V22, P291
Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006
Salvalaggio PR, 2014, TRANSPLANTATION, V98, P241, DOI 10.1097/TP.0000000000000198

Coleções

Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/37
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo